A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London. Results have been published in NEJM Evidence.

Research carried out by St George’s, University of London into tuberculosis treatments has clearly shown the ‘persistent bacteria’ that make treating the disease so difficult for the first time, using a new combination therapy.